Pulmonary marginal zone B-cell lymphoma of MALT type-What is a prognostic factor and which is the optimal treatment, operation, or chemotherapy? Consortium for Improving Survival of Lymphoma (CISL) Study

Sung Yong Oh, Won Seog Kim, Jin Seok Kim, Seok Jin Kim, Hyuk Chan Kwon, Dae Ho Lee, Jong Ho Won, In Gyu Hwang, Min Kyoung Kim, Soon Il Lee, Yee Soo Chae, Deok Hwan Yang, Gyeong Won Lee, Chul Won Choi, Jinny Park, Cheolwon Suh, Hyo Jin Kim

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Abstracts: Pulmonary marginal zone B-cell lymphoma of the MALT type (P-MZL) is a relatively rare form of lymphoma. We conducted a retrospective analysis of the clinical features and treatment outcomes of P-MZL for the evaluation of prognostic factors, and to collect information about the optimal treatment modality for this condition. From 1991 to 2008, a total of 61 patients with biopsy-confirmed P-MZL were retrospectively analyzed. The median age of our subjects was 60 (range, 34-79) years. Twenty-five of the patients (41%) were initially diagnosed without any symptoms. Video-assisted thoracic surgery was utilized for diagnosis in 19 patients (31%). Thirty-eight patients' conditions (62%) involved a single lobe. Lung lesions were bilateral in 15 patients (25%). Eleven patients evidenced synchronous involvement of extra-pulmonary site MZL. Overall, 56 of 61 patients were treated with surgery (n∈=∈22), chemotherapy (n∈=∈28), or radiotherapy (n∈=∈6). Among them, 46 patients achieved complete or partial remission. The median time to progression (TTP) was 5.6 (95% CI, 2.6-8.6) years. Five patients died during follow-up. Extra-pulmonary MZL and LN involvement were shown to be poor prognostic factors for TTP. We noted no differences between the operation group and chemotherapy group in terms of TTP. P-MZL tends to be an indolent disease-characterized by prolonged survival with frequent relapses. This is similar to what is observed with other cases of MALT-type site MZL. In order to conserve lung function and reduce the risks of operation, chemotherapy should be considered as a first-line option for the treatment of P-MZL.

Original languageEnglish
Pages (from-to)563-568
Number of pages6
JournalAnnals of Hematology
Volume89
Issue number6
DOIs
Publication statusPublished - 2010 Jun

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Dive into the research topics of 'Pulmonary marginal zone B-cell lymphoma of MALT type-What is a prognostic factor and which is the optimal treatment, operation, or chemotherapy? Consortium for Improving Survival of Lymphoma (CISL) Study'. Together they form a unique fingerprint.

  • Cite this

    Oh, S. Y., Kim, W. S., Kim, J. S., Kim, S. J., Kwon, H. C., Lee, D. H., Won, J. H., Hwang, I. G., Kim, M. K., Lee, S. I., Chae, Y. S., Yang, D. H., Lee, G. W., Choi, C. W., Park, J., Suh, C., & Kim, H. J. (2010). Pulmonary marginal zone B-cell lymphoma of MALT type-What is a prognostic factor and which is the optimal treatment, operation, or chemotherapy? Consortium for Improving Survival of Lymphoma (CISL) Study. Annals of Hematology, 89(6), 563-568. https://doi.org/10.1007/s00277-009-0875-7